Baxter International, Inc. wins patent infringement case

Baxter International, Inc. has won a long-running battle in a patent infringement suit ( Fresenius USA, Inc. et al v. Baxter International Inc. et al.) against Fresenius Medical Care involving Fresenius ' Number One - selling hemodialysis machine in the United States.

The U.S. District Court for the Northern District of California today issued opinions permanently enjoining Fresenius from manufacturing its flagship product affirming it infringes on Baxter ' s technology and awarding damages to Baxter. Bell, Boyd & Lloyd LLP represented Baxter in the case.

The Order, written by Judge Saundra B. Armstrong, requires that Fresenius stop making, using or selling the 2008K hemodialysis machine effective January 1, 2009. Judge Armstrong also imposed a 10% royalty on the sales price of each infringing machines sold from now until January 1, 2009 and further imposed a 7% royalty on all disposable products used with the infringing 2008K hemodialysis machines. The 2008K is, according to Fresenius, its “ cornerstone product ” and is the best selling hemodialysis machine in the marketplace, with over 90 percent market share.

In granting the injunction, Judge Armstrong noted that much of the hardship that Fresenius will face from the injunction is its own doing because it did not take any steps to design around the patents-in-suit: “ [ i ] t is Fresenius's burden, and not Baxter's, to taste the bitter fruit of its own inaction. ”

In a February 2007 ruling, Judge Armstrong upheld the validity of Baxter ' s patents that had been challenged by Fresenius in a 2003 law suit, ruling that Fresenius failed to introduce substantial evidence of invalidity.

Baxter is represented by Bell, Boyd & Lloyd LLP. The trial team included Michael J. Abernathy, Alan Barry, Kara E.F. Cenar, Sanjay K. Murthy, Adam L. Marchuk, Brian J. Arnold and Marron Mahoney.

Baxter International is based in Illinois and, through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other conditions.

http://www.baxter.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2023, January 12). Baxter International, Inc. wins patent infringement case. News-Medical. Retrieved on April 19, 2024 from https://www.news-medical.net/news/2008/04/07/37015.aspx.

  • MLA

    Baxter International Inc.. "Baxter International, Inc. wins patent infringement case". News-Medical. 19 April 2024. <https://www.news-medical.net/news/2008/04/07/37015.aspx>.

  • Chicago

    Baxter International Inc.. "Baxter International, Inc. wins patent infringement case". News-Medical. https://www.news-medical.net/news/2008/04/07/37015.aspx. (accessed April 19, 2024).

  • Harvard

    Baxter International Inc.. 2023. Baxter International, Inc. wins patent infringement case. News-Medical, viewed 19 April 2024, https://www.news-medical.net/news/2008/04/07/37015.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A